Leveraging lessons learned from the COVID-19 pandemic for HIV

Thomas Calder; Tina Tong; Dale J. Hu; Jerome H. Kim; Karen L. Kotloff; Richard A. Koup; Mary A. Marovich; M. Juliana McElrath; Sarah W. Read; Merlin L. Robb; Philip O. Renzullo; M. Patricia D’Souza

doi:10.1038/s43856-022-00175-8

Leveraging lessons learned from the COVID-19 pandemic for HIV

Thomas Calder, Tina Tong, Dale J. Hu, Jerome H. Kim, Karen L. Kotloff, Richard A. Koup, Mary A. Marovich, M. Juliana McElrath, Sarah W. Read, Merlin L. Robb, Philip O. Renzullo, M. Patricia D’Souza^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.

Original language	English
Article number	110
Journal	Communications Medicine
Volume	2
Issue number	1
DOIs	https://doi.org/10.1038/s43856-022-00175-8
State	Published - 1 Dec 2022

Access to Document

10.1038/s43856-022-00175-8

Cite this

@article{7e4655476ec04599b00151a3ad5c3eae,

title = "Leveraging lessons learned from the COVID-19 pandemic for HIV",

abstract = "The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.",

author = "Thomas Calder and Tina Tong and Hu, {Dale J.} and Kim, {Jerome H.} and Kotloff, {Karen L.} and Koup, {Richard A.} and Marovich, {Mary A.} and McElrath, {M. Juliana} and Read, {Sarah W.} and Robb, {Merlin L.} and Renzullo, {Philip O.} and D{\textquoteright}Souza, {M. Patricia}",

note = "Publisher Copyright: {\textcopyright} 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",

year = "2022",

month = dec,

day = "1",

doi = "10.1038/s43856-022-00175-8",

language = "English",

volume = "2",

journal = "Communications Medicine",

issn = "2730-664X",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Leveraging lessons learned from the COVID-19 pandemic for HIV

AU - Calder, Thomas

AU - Tong, Tina

AU - Hu, Dale J.

AU - Kim, Jerome H.

AU - Kotloff, Karen L.

AU - Koup, Richard A.

AU - Marovich, Mary A.

AU - McElrath, M. Juliana

AU - Read, Sarah W.

AU - Robb, Merlin L.

AU - Renzullo, Philip O.

AU - D’Souza, M. Patricia

PY - 2022/12/1

Y1 - 2022/12/1

N2 - The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.

AB - The rapid development of COVID-19 vaccines and their deployment in less than a year is an unprecedented scientific, medical, and public health achievement. This rapid development leveraged knowledge from decades of HIV/AIDS research and advances. However, the search for an HIV vaccine that would contribute to a durable end to the HIV pandemic remains elusive. Here, we draw from the US government experience and highlight lessons learned from COVID-19 vaccine development, which include the importance of public-private partnerships, equitable inclusion of populations impacted by the infectious pathogen, and continued investment in basic research. We summarize key considerations for an accelerated and re-energized framework for developing a safe and efficacious HIV vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85142734281&partnerID=8YFLogxK

U2 - 10.1038/s43856-022-00175-8

DO - 10.1038/s43856-022-00175-8

M3 - Article

AN - SCOPUS:85142734281

SN - 2730-664X

VL - 2

JO - Communications Medicine

JF - Communications Medicine

IS - 1

M1 - 110

ER -